Aster DM Quality Care will participate in a non-deal roadshow organized by Kotak Mahindra Capital Company Limited from August 10, 2026, to August 14, 2026. The healthcare provider aims to engage with investors and analysts through a series of group and one-to-one meetings held across Mumbai and Singapore. These interactions are scheduled during business hours, from 9:00 AM to 6:00 PM IST/SGT, allowing for flexible participation via both virtual platforms and in-person attendance.

The company disclosed the schedule pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory filing ensures transparency regarding management's engagement with the investment community. The intimation was submitted to BSE Limited and The National Stock Exchange of India Limited on May 5, 2026, and is also available on the company’s official website.

Roadshow Schedule Details

The upcoming events are structured to facilitate detailed discussions between Aster DM Quality Care’s representatives and market participants. The format includes both broad group presentations and individual one-to-one sessions to address specific investor queries.

Compliance and Information Disclosure

Aster DM Quality Care emphasized that no unpublished price-sensitive information (UPSI) will be shared during these meetings. This compliance measure aligns with SEBI’s insider trading regulations, ensuring that all material information is disseminated equally to all stakeholders through formal channels. The company noted that the schedule is subject to change based on exigencies involving either the investors or the company.

Hemish Purushottam, Company Secretary and Compliance Officer of Aster DM Quality Care Limited, signed the disclosure. The company, formerly known as Aster DM Healthcare Limited, maintains its registered office in Hyderabad and its corporate office in Bengaluru. The roadshow serves as a standard mechanism for listed entities to maintain regular dialogue with their shareholder base without implying any immediate transactional activity.

aster dm quality care has moved to consolidate its ownership in United CIIGMA Institute of Medical Sciences Private Limited (UCIMSPL) while exiting an underperforming hospital asset. At a meeting held on August 5, 2026, the Board of Directors approved the acquisition of up to an additional 12% equity stake in UCIMSPL for a cash consideration of up to ₹40.93 crore. This transaction stems from the exercise of put option rights by certain minority shareholders under the Shareholders’ Agreement dated June 10, 2022. In a separate strategic decision, the company terminated the operations and management agreement for Aster G. Madegowda Hospital in Maddur, citing failure to achieve anticipated scale and profitability.

The acquisition deepens Aster DM Quality Care’s control over UCIMSPL, which reported a turnover of ₹153.64 crore for the financial year ended March 31, 2026. The target entity, incorporated on February 7, 2011, operates in the healthcare industry and is headquartered in Chhatrapati Sambhajnagar. UCIMSPL has an authorized share capital of ₹52 crore and a paid-up share capital of ₹51.36 crore. The Board confirmed that the transaction is conducted at arm’s length and does not require further governmental or regulatory approvals. The acquisition is expected to be completed within the next one to two months.

Conversely, the company is winding down its presence in Maddur. The operations and management agreement for Aster G. Madegowda Hospital, originally entered into on April 1, 2023, will close on August 5, 2026, or such effective date as finalized between the parties. The facility contributed only 0.15% of the entity’s revenue during the last financial year. Management stated that the hospital incurred sustained operating losses since commencement and failed to achieve the anticipated operational scale, prompting the strategic review and subsequent exit.

The Board also approved the convening of the 18th Annual General Meeting (AGM) on Monday, September 28, 2026, at 11:30 A.M. IST. The meeting will be conducted through video conferencing or other audio-video means. Additionally, the Board approved the Notice of Postal Ballot to seek shareholder approval for special business. Both notices will be dispatched to shareholders and stock exchanges in due course.

Transaction Details

Strategic Implications

The dual action highlights a shift toward consolidating profitable assets while shedding non-core, loss-making units. By exercising the put option rights, Aster DM Quality Care avoids potential dilution or governance friction with minority stakeholders in UCIMSPL, thereby strengthening its vertical integration in the healthcare sector. Simultaneously, the exit from the Maddur hospital removes a drag on overall profitability, allowing management to focus resources on higher-performing facilities. The minimal revenue contribution of the Maddur unit (0.15%) suggests the financial impact of the exit will be negligible, while the consolidation of UCIMSPL secures control over a significantly larger revenue base.